Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.81 | N/A | -67.59% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.81 | N/A | -67.59% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current economic environment but emphasized their commitment to operational stability. They did not provide any updates on revenue expectations.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on maintaining operational efficiency during uncertain times.
PTC Therapeutics reported a larger-than-expected loss per share, which contributed to a 4.89% decline in stock price following the earnings announcement. The lack of revenue figures and guidance indicates uncertainty about future performance. Investors may be cautious as the company navigates a challenging economic landscape.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NXP SEMICONDUCTORS N
Apr 27, 2020